Dexamethasone Infusion to the Adventitia to Enhance Clinical Efficacy After Femoropopliteal Revascularization

Inclusion Criteria: * Patient is \> 40 years and \< 80 years of age * Patient has severe, lifestyle-limiting claudication or critical limb ischemia (Rutherford classification 3-6) * Patient has TASC II A, B or C disease, SFA revascularization is preferred over medical management, and endovascular approach is preferred revascularization strategy * Patient has a resting ABI of \<0.9 or an abnormal treadmill ABI. Patients with incompressible arteries must have a TBI \<0.8 * Patient has at least 1 infra-popliteal run-off vessel with patency to the ankle without a \>50% stenosis * Successful crossing of the lesion with guidewire and successful atherectomy or angioplasty with residual stenosis \<30% as compared to the reference vessels * Atherectomy procedure does not result in embolization, arteriovenous fistula or perforation * Patient agrees to return for a clinical assessment duplex ultrasound at 1, 3, 6, 9, 12 and 24 months (routine clinical care) Exclusion Criteria: * Patient is simultaneously participating in another investigational drug or device study * Patient is pregnant or breast-feeding * Patient has cancer, autoimmune disease, bone marrow or organ transplant, or other concurrent medical illness requiring immunosuppressive therapy * Patient has end-stage renal disease and chronic kidney disease (eGFR\<30) * Patient has an active infection * Patient has a known hypersensitivity or contraindication to heparin, contrast agents, excipients of Dexamethasone Sodium Phosphate Injection, USP, dexamethasone, or other glucocorticoids * Patient has a life expectancy of less than one year